Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: BACTROBAN

« Back to Dashboard

Bactroban is a drug marketed by Glaxosmithkline and is included in three NDAs. It is available from seven suppliers. There are two patents protecting this drug.

The generic ingredient in BACTROBAN is mupirocin. There are nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the mupirocin profile page.

Summary for Tradename: BACTROBAN

Suppliers: see list7

Pharmacology for Tradename: BACTROBAN

Clinical Trials for: BACTROBAN

A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.
Status: Completed Condition: Secondarily Infected Traumatic Skin Lesions

Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection
Status: Completed Condition: Staphylococcus Aureus; HIV Infections

Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
Status: Recruiting Condition: Staphylococcal Infection

Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting
Status: Completed Condition: Surgical Site Infections

Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin
Status: Completed Condition: Surgical Site Infection

Preventing Staphylococcal (Staph) Infection
Status: Completed Condition: Staphylococcal Infections

Safety and Efficacy of Intranasal and Topical Mupirocin in Eradicating Colonization With Staphylococcus Aureus (SA) in Critically Ill Infants - a Phase 2, Multi-Center, Open Label, Randomized Trial
Status: Recruiting Condition: Staphylococcal Infection

Topical Gentamicin Cream Versus Alternating Gentamicin and Mupirocin Cream in Peritoneal Dialysis
Status: Not yet recruiting Condition: Rate of Exit Site Infection; Rate of Atypical Mycobacterial Infection; Rate of Peritoneal Dialysis

Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections
Status: Completed Condition: Cross Infection; Staphylococcal Infections

Total Occlusive Ionic Silver-containing Dressing vs Mupirocin Ointment Application vs Conventional Dressing in Elective Colorectal Surgery: Effect on Incisional Surgical Site Infection
Status: Completed Condition: Incisional Surgical Site Infections

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
mupirocin calcium
CREAM;TOPICAL050746Dec 11, 1997RXYes5,569,672<disabled><disabled>
OINTMENT;TOPICAL050591Dec 31, 1987RXYes<disabled><disabled>
mupirocin calcium
OINTMENT;NASAL050703Sep 18, 1995RXYes5,569,672<disabled><disabled>
mupirocin calcium
CREAM;TOPICAL050746Dec 11, 1997RXYes6,025,389<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology